Cargando…
IRONMAN adds support for iron repletion in HF
The IRONMAN trial adds further support to the known benefits of intravenous iron therapy in patients with heart failure (HF) with reduced ejection fraction and iron deficiency, but narrowly misses the primary end point of hospitalization for HF and cardiovascular death.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684863/ https://www.ncbi.nlm.nih.gov/pubmed/36414679 http://dx.doi.org/10.1038/s41569-022-00815-5 |